Nicox SA an international ophthalmology company, today announced that patent EP 3,769,753, expiring in 2040 and covering the Company’s product candidate in development for blepharitis, NCX 4251, has been issued by the European Patent Office (EPO). The patent covers ophthalmic suspensions comprising a specific form of fluticasone propionate nanocrystals and the method for manufacturing the ophthalmic suspensions. Examination of corresponding patent applications providing exclusivity in the United States (U.S.), China, Japan and other territories is in process.
- Read more about Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/nicox-is-granted-patent-for-blepharitis-product-candidate-ncx-4251-in-europe
No comments:
Post a Comment